Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We have downgraded our recommendation on Hilltop Holdings Inc. ( HTH - Analyst Report ) to Neutral from Outperform based on weak global cues, amid which expenses and cash outflow are expected to remain elevated. However, a sound capital position along with a risk-free balance sheet has also paved way for resumption of share buybacks.
Hilltop broke even in the third quarter of 2011 against the loss of 13 cents in the year-ago quarter and the Zacks Consensus Estimate of a loss of 22 cents per share. Net income also rose to $0.25 million from a loss of $7.2 million in the prior-year quarter.
Results benefited from modest underwriting profitability, premiums growth, net realized gains and investment income that drove the top line. However, this growth was offset by higher-than-expected expenses, which in turn hampered the combined ratio and resulted in operating cash outflow.
Nevertheless, Hilltop’s vast exposure to the weather-risk prone areas increases the loss and loss adjustment expenses, which also deteriorates its claim ratios, combined ratio and underwriting expense ratios. Additionally, Hilltop’s sole dependence on inorganic growth (from the NLASCO acquisition) amid intensely competitive insurance industry and volatile economy continues to be the cause of concern in the intermediate term.
On the flip side though, Hilltop’s balance sheet remained risk free and fairly liquid despite the challenging operating environment. Moreover, Hilltop’s investment, debt and securities along with its subsidiaries are well poised in the market owing to their superior financial strength and credit ratings. This leaves excess capital and ample scope for more meaningful acquisitions and alliances for the company’s long-term growth.
Moreover, Hilltop’s healthy capital deployment strategy is also reflected from the new $100 million share repurchase program announced in November 2011. While the repurchases will be initiated through open market operations, depending on the market conditions, the program is scheduled to expire on November 1, 2012. The share repurchase program also bodes well for imbibing confidence in the shareholders.
Overall, Hilltop’s future performance will largely depend on the prudent deployment of its reserves. We thus, expect the company to grow and evolve in the upcoming quarters by expanding its operations, which should further drive the desired upside in the stock. Nevertheless, a waiting period remains for the clearance of the smog and for gaining better visibility, which justifies our current Neutral outlook.
Weighing all the pros and cons, the Zacks Consensus Estimate of earnings for fourth-quarter 2011 are currently pegged at 2 cents, in line with the year-ago quarter. However, for 2011, loss is estimated to be 19 cents, down from a loss of 24 cents in 2010. Meanwhile, earnings are expected to grow to 7 cents in 2012, significantly up from the estimated loss in 2011.
Additionally, the quantitative Zacks Rank for Hilltop is currently #3, translating into a short-term Hold rating, while the long-term stance remains Neutral.
Read the full Analyst Report on HTH